Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Patients with overactive bladder (OAB) who have failed an oral therapy have a number of treatment options including onabotulinumtoxinA (onabotA) injection, percutaneous tibial nerve stimulation (PTNS), or implantable sacral neurostimulation (SNS) device. This analysis estimates the cost-effectiveness of onabotA 100U compared to PTNS and SNS from the US payer perspective.
Interstitial Cystitis (IC) is a debilitating condition that affects up to five percent of the United States (US) population (Clemens, 2015). The condition is characterized by bladder pain, urinary urgency and frequency, and in some patients, bladder lesions called Hunner’s Lesions (HL). Patients with HL experience a clinical course distinct from patients without HL. Prior research describing the burden of IC is outdated and lacks HL-level detail.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
